Three Neuroendocrine Peptides, Two Distinct Systems
CJC-1295, ipamorelin and PT-141 are often listed together because all three act on hypothalamic–pituitary signalling. Mechanistically, though, they fall into two separate groups. CJC-1295 (as Mod GRF 1-29) and ipamorelin both act on the growth hormone axis — through the GHRH receptor and the ghrelin receptor respectively. PT-141 acts on an unrelated system, the central melanocortin receptors.
This article reviews the published pharmacology of each, the evidence for synergy between the two secretagogues, and the design choices that make combination studies interpretable. It is written for laboratory researchers and contains no dosing or human-use guidance.
CJC-1295 (Mod GRF 1-29): GHRH Receptor Agonism
Mod GRF 1-29 is a truncated analogue of growth hormone-releasing hormone carrying four substitutions — D-Ala2, Gln8, Ala15 and Leu27 — that improve resistance to DPP-4 cleavage and chemical degradation compared with sermorelin. It activates the GHRH receptor on pituitary somatotrophs, signalling mainly through Gs, adenylyl cyclase and cAMP to stimulate GH synthesis and release.
Without the Drug Affinity Complex (DAC), the analogue has a short half-life on the order of 30 minutes, so it produces discrete pulses rather than the sustained elevation reported for CJC-1295 with DAC. That distinction matters when choosing a model: short-acting analogues preserve the physiological pulsatile pattern researchers often want to study.
Ipamorelin: Selective Ghrelin-Receptor Agonism
Ipamorelin is a pentapeptide agonist of the growth hormone secretagogue receptor, GHS-R1a — the receptor for the gut hormone ghrelin. GHS-R1a couples mainly through Gq, phospholipase C and intracellular calcium. In the original swine studies, ipamorelin released growth hormone without the significant ACTH and cortisol increases seen with earlier secretagogues such as GHRP-6 and GHRP-2, which is why it is described as selective.
The GHRH–Ghrelin-Receptor Synergy
The rationale for studying a GHRH analogue together with a ghrelin-receptor agonist is well established. Pharmacology studies since the 1990s have reported that co-administering GHRH and a growth hormone secretagogue produces GH release greater than the sum of either alone. Proposed mechanisms include:
- Complementary second messengers — cAMP from the GHRH receptor and calcium mobilisation from GHS-R1a converge on GH exocytosis.
- Functional opposition to somatostatin — ghrelin-receptor signalling counteracts somatostatin's inhibitory tone, amplifying the GHRH response.
- Hypothalamic effects — GHS-R1a agonists also act on hypothalamic GHRH neurons, adding a central component.
This is the basis for co-lyophilized research blends such as our CJC-1295 and Ipamorelin combination. Note that most synergy data come from GHRH itself or other secretagogues; studies of this specific fixed-ratio pairing are more limited.
PT-141: A Separate Melanocortin Pathway
PT-141 (bremelanotide) is a cyclic heptapeptide analogue of α-MSH and a non-selective melanocortin agonist with activity at MC4R and MC3R, as well as MC1R. Its research interest lies in central melanocortin circuits — particularly hypothalamic MC4R signalling — rather than in the growth hormone axis. Clinical pharmacology studies of the approved product also reported transient blood-pressure increases, a relevant consideration in any in-vivo model.
There is no established mechanistic synergy between PT-141 and growth hormone secretagogues. When the two appear in the same study, they should be treated as independent interventions on separate receptor systems. Full specifications are on the PT-141 page.
Designing an Interpretable Combination Study
- Use a factorial design. Synergy can only be demonstrated against each compound alone and a vehicle control — compare the combination with the sum of the single-agent responses.
- Run concentration–response curves for each peptide before testing combinations, so the combination is tested at informative points on each curve.
- Match readouts to mechanism. cAMP accumulation for GHRH-receptor activity, calcium flux or IP-one for GHS-R1a, and GH secretion (ELISA) from pituitary cells as the integrated endpoint; MC4R activity is typically assessed by cAMP in receptor-expressing cell lines.
- Account for pulsatility and desensitisation. GH release is pulsatile and GHS-R1a can desensitise with repeated exposure, so sampling schedules and exposure timing shape the result.
- Consider species differences in receptor pharmacology when moving between rodent, porcine and human-derived systems.
- Verify every batch. Confirm identity by mass spectrometry and purity by HPLC on the batch COA — for blends, check that both components are reported.
For guidance on evaluating a supplier's analytical data, see our guide to choosing a peptide source.
Frequently Asked Questions
Is there evidence of synergy between CJC-1295 and ipamorelin?
Synergy between GHRH-receptor and ghrelin-receptor agonists is well documented in pharmacology studies: co-administration produces more GH release than either alone. Most of that evidence comes from GHRH itself or other secretagogues; data on this specific pairing are more limited.
Does PT-141 interact with growth hormone secretagogues?
No mechanistic synergy has been established. PT-141 acts on central melanocortin receptors (MC4R, MC3R), a system separate from the GHRH and ghrelin receptors that CJC-1295 and ipamorelin target.
Why doesn't this guide include dosages or protocols?
Our compounds are sold strictly for in-vitro laboratory research. We do not provide dosing, administration or human-use guidance of any kind; study concentrations should be determined from the primary literature and your own concentration–response experiments.
What is the difference between CJC-1295 with and without DAC?
CJC-1295 with DAC carries an albumin-binding group that extends its half-life to several days. The no-DAC form (Mod GRF 1-29) is short-acting, preserving a pulsatile GH release pattern.
References & Further Reading
Raun K et al., Eur J Endocrinol 1998; Teichman SL et al., J Clin Endocrinol Metab 2006; Pfaus JG et al., Proc Natl Acad Sci USA 2004; Kingsberg SA et al., Obstet Gynecol 2019.